Cargando…

Improving the Effects of Imeglimin on Endothelial Function: A Prospective, Single-Center, Observational Study

INTRODUCTION: Endothelial dysfunction is a risk factor for cardiovascular disease in patients with diabetes. We hypothesized that imeglimin, a novel oral hypoglycemic agent, would improve endothelial function. METHODS: In this study, imeglimin was administered to patients with type 2 diabetes and Hb...

Descripción completa

Detalles Bibliográficos
Autores principales: Uchida, Taisuke, Ueno, Hiroaki, Konagata, Ayaka, Taniguchi, Norifumi, Kogo, Fumiko, Nagatomo, Yuma, Shimizu, Koichiro, Yamaguchi, Hideki, Shimoda, Kazuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9981829/
https://www.ncbi.nlm.nih.gov/pubmed/36732433
http://dx.doi.org/10.1007/s13300-023-01370-z
_version_ 1784900193160790016
author Uchida, Taisuke
Ueno, Hiroaki
Konagata, Ayaka
Taniguchi, Norifumi
Kogo, Fumiko
Nagatomo, Yuma
Shimizu, Koichiro
Yamaguchi, Hideki
Shimoda, Kazuya
author_facet Uchida, Taisuke
Ueno, Hiroaki
Konagata, Ayaka
Taniguchi, Norifumi
Kogo, Fumiko
Nagatomo, Yuma
Shimizu, Koichiro
Yamaguchi, Hideki
Shimoda, Kazuya
author_sort Uchida, Taisuke
collection PubMed
description INTRODUCTION: Endothelial dysfunction is a risk factor for cardiovascular disease in patients with diabetes. We hypothesized that imeglimin, a novel oral hypoglycemic agent, would improve endothelial function. METHODS: In this study, imeglimin was administered to patients with type 2 diabetes and HbA1c ≥ 6.5% who were not receiving insulin therapy. A meal tolerance test (592 kcal, glucose 75.0 g, fat 28.5 g) was performed before and 3 months after administration, and endothelial function, blood glucose, insulin, glucagon, and triglycerides were evaluated. Endothelial function was assessed by flow-mediated dilation (FMD). RESULTS: Twelve patients (50% male) with a median age of 55.5 years old (interquartile range [IQR] 51.3–66.0) were enrolled. Fasting FMD did not differ before or 3 months after imeglimin administration (from 6.1 [3.9–8.5] to 6.6 [3.9–9.0], p = 0.092), but 2 h postprandial FMD was significantly improved 3 months after imeglimin administration (from 2.3 [1.9–3.4] to 2.9 [2.4–4.7], p = 0.013). In terms of the glucose profile, imeglimin administration significantly improved HbA1c (from 7.2 ± 0.6% to 6.9 ± 0.6%, p = 0.007), fasting glucose (from 138 ± 19 mg/dL to 128 ± 20 mg/dL, p = 0.020), and 2 h postprandial glucose (from 251 ± 47 mg/dL to 215 ± 68 mg/dL, p = 0.035). The change in 2 h postprandial FMD between before and 3 months after imeglimin administration (Δ2 h postprandial FMD) was negatively correlated with Δ2 h postprandial glucose (r = − 0.653, p = 0.021) in a univariate correlation coefficient analysis. Both patients with and without decreased postprandial glucose 3 months after imeglimin administration had improved postprandial FMD. CONCLUSION: In this small study, imeglimin administration improved 2 h postprandial FMD. Both glycemic control-dependent and -independent mechanisms might contribute to improved endothelial function. TRIAL REGISTRATION: This research was registered in the University Hospital Medical Information Network (UMIN, UMIN000046311). SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s13300-023-01370-z.
format Online
Article
Text
id pubmed-9981829
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-99818292023-03-04 Improving the Effects of Imeglimin on Endothelial Function: A Prospective, Single-Center, Observational Study Uchida, Taisuke Ueno, Hiroaki Konagata, Ayaka Taniguchi, Norifumi Kogo, Fumiko Nagatomo, Yuma Shimizu, Koichiro Yamaguchi, Hideki Shimoda, Kazuya Diabetes Ther Original Research INTRODUCTION: Endothelial dysfunction is a risk factor for cardiovascular disease in patients with diabetes. We hypothesized that imeglimin, a novel oral hypoglycemic agent, would improve endothelial function. METHODS: In this study, imeglimin was administered to patients with type 2 diabetes and HbA1c ≥ 6.5% who were not receiving insulin therapy. A meal tolerance test (592 kcal, glucose 75.0 g, fat 28.5 g) was performed before and 3 months after administration, and endothelial function, blood glucose, insulin, glucagon, and triglycerides were evaluated. Endothelial function was assessed by flow-mediated dilation (FMD). RESULTS: Twelve patients (50% male) with a median age of 55.5 years old (interquartile range [IQR] 51.3–66.0) were enrolled. Fasting FMD did not differ before or 3 months after imeglimin administration (from 6.1 [3.9–8.5] to 6.6 [3.9–9.0], p = 0.092), but 2 h postprandial FMD was significantly improved 3 months after imeglimin administration (from 2.3 [1.9–3.4] to 2.9 [2.4–4.7], p = 0.013). In terms of the glucose profile, imeglimin administration significantly improved HbA1c (from 7.2 ± 0.6% to 6.9 ± 0.6%, p = 0.007), fasting glucose (from 138 ± 19 mg/dL to 128 ± 20 mg/dL, p = 0.020), and 2 h postprandial glucose (from 251 ± 47 mg/dL to 215 ± 68 mg/dL, p = 0.035). The change in 2 h postprandial FMD between before and 3 months after imeglimin administration (Δ2 h postprandial FMD) was negatively correlated with Δ2 h postprandial glucose (r = − 0.653, p = 0.021) in a univariate correlation coefficient analysis. Both patients with and without decreased postprandial glucose 3 months after imeglimin administration had improved postprandial FMD. CONCLUSION: In this small study, imeglimin administration improved 2 h postprandial FMD. Both glycemic control-dependent and -independent mechanisms might contribute to improved endothelial function. TRIAL REGISTRATION: This research was registered in the University Hospital Medical Information Network (UMIN, UMIN000046311). SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s13300-023-01370-z. Springer Healthcare 2023-02-03 2023-03 /pmc/articles/PMC9981829/ /pubmed/36732433 http://dx.doi.org/10.1007/s13300-023-01370-z Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Original Research
Uchida, Taisuke
Ueno, Hiroaki
Konagata, Ayaka
Taniguchi, Norifumi
Kogo, Fumiko
Nagatomo, Yuma
Shimizu, Koichiro
Yamaguchi, Hideki
Shimoda, Kazuya
Improving the Effects of Imeglimin on Endothelial Function: A Prospective, Single-Center, Observational Study
title Improving the Effects of Imeglimin on Endothelial Function: A Prospective, Single-Center, Observational Study
title_full Improving the Effects of Imeglimin on Endothelial Function: A Prospective, Single-Center, Observational Study
title_fullStr Improving the Effects of Imeglimin on Endothelial Function: A Prospective, Single-Center, Observational Study
title_full_unstemmed Improving the Effects of Imeglimin on Endothelial Function: A Prospective, Single-Center, Observational Study
title_short Improving the Effects of Imeglimin on Endothelial Function: A Prospective, Single-Center, Observational Study
title_sort improving the effects of imeglimin on endothelial function: a prospective, single-center, observational study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9981829/
https://www.ncbi.nlm.nih.gov/pubmed/36732433
http://dx.doi.org/10.1007/s13300-023-01370-z
work_keys_str_mv AT uchidataisuke improvingtheeffectsofimegliminonendothelialfunctionaprospectivesinglecenterobservationalstudy
AT uenohiroaki improvingtheeffectsofimegliminonendothelialfunctionaprospectivesinglecenterobservationalstudy
AT konagataayaka improvingtheeffectsofimegliminonendothelialfunctionaprospectivesinglecenterobservationalstudy
AT taniguchinorifumi improvingtheeffectsofimegliminonendothelialfunctionaprospectivesinglecenterobservationalstudy
AT kogofumiko improvingtheeffectsofimegliminonendothelialfunctionaprospectivesinglecenterobservationalstudy
AT nagatomoyuma improvingtheeffectsofimegliminonendothelialfunctionaprospectivesinglecenterobservationalstudy
AT shimizukoichiro improvingtheeffectsofimegliminonendothelialfunctionaprospectivesinglecenterobservationalstudy
AT yamaguchihideki improvingtheeffectsofimegliminonendothelialfunctionaprospectivesinglecenterobservationalstudy
AT shimodakazuya improvingtheeffectsofimegliminonendothelialfunctionaprospectivesinglecenterobservationalstudy